Difference between revisions of "Team:NTU-LIHPAO-Taiwan/Collaborations"

 
(25 intermediate revisions by 2 users not shown)
Line 506: Line 506:
 
/*-------------------------------------------*/
 
/*-------------------------------------------*/
  
−
.Container_Article_Picture {
+
.Article_Spacing {
−
height: 280px;
+
width: 100%;
 +
height: 5px;
 +
}
 +
 
 +
.Container_Article_Picture1 {
 +
height: 645px;
 +
width: 100%;
 +
padding-top: 25px;
 +
padding-bottom: 25px;
 +
}
 +
 
 +
.Article_Picture1 {
 +
width: 465px;
 +
height: auto;
 +
left: 50%;
 +
right: auto;
 +
background-color: #FFF;
 +
margin: 0 0 0 -232px;
 +
position: absolute;
 +
}
 +
 
 +
.Article_PictureText1 {
 +
width: 415px;
 +
height: auto;
 +
padding-left: 25px;
 +
padding-right: 25px;
 +
border-top-width: 2px;
 +
border-top-style: dashed;
 +
border-top-color: #fe5838;
 +
}
 +
 
 +
.Container_Article_Picture2 {
 +
height: 380px;
 +
width: 100%;
 +
padding-top: 25px;
 +
padding-bottom: 25px;
 +
}
 +
 
 +
.Article_Picture2 {
 +
width: 550px;
 +
height: auto;
 +
left: 50%;
 +
right: auto;
 +
background-color: #FFF;
 +
margin: 0 0 0 -275px;
 +
position: absolute;
 +
}
 +
 
 +
.Article_PictureText2 {
 +
width: 500px;
 +
height: auto;
 +
padding-left: 25px;
 +
padding-right: 25px;
 +
border-top-width: 2px;
 +
border-top-style: dashed;
 +
border-top-color: #fe5838;
 +
}
 +
 
 +
.Container_Article_Picture3 {
 +
height: 380px;
 
width: 100%;
 
width: 100%;
 
padding-top: 25px;
 
padding-top: 25px;
Line 513: Line 572:
 
}
 
}
  
−
.Article_Picture {
+
.Article_Picture3 {
−
width: 480px;
+
width: 550px;
 
height: auto;
 
height: auto;
 
left: 50%;
 
left: 50%;
 
right: auto;
 
right: auto;
 
background-color: #FFF;
 
background-color: #FFF;
−
margin: 0 0 0 -240px;
+
margin: 0 0 0 -275px;
 
position: absolute;
 
position: absolute;
 
}
 
}
  
−
.Article_PictureText {
+
.Article_PictureText3 {
−
width: 430px;
+
width: 500px;
 
height: auto;
 
height: auto;
 
padding-left: 25px;
 
padding-left: 25px;
Line 752: Line 811:
 
<div class="Slidemenu">
 
<div class="Slidemenu">
 
<ul>
 
<ul>
−
<li><div class=width_small><div id=Position_Now><a href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan">Home</a></div></div>
+
<li><div class=width_small><a href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan">Home</a></div>
 
</li>
 
</li>
  
Line 777: Line 836:
 
<li><a href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Basic_Part">Basic Parts</a></li>
 
<li><a href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Basic_Part">Basic Parts</a></li>
 
<li><a href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Composite_Part">Composite Parts</a></li>
 
<li><a href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Composite_Part">Composite Parts</a></li>
−
<li><a href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Part_Collection">Part Collection</a></li>
 
 
</ul>
 
</ul>
 
</li>
 
</li>
Line 787: Line 845:
 
</li>
 
</li>
 
 
−
<li><div class=width_small span style="cursor:default"><a>Society</a></div>
+
<li><div class=width_small span style="cursor:default"><div id=Position_Now><a>Society</a></div></div>
 
<ul class="subs">
 
<ul class="subs">
 
<li><a href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Practices">Human Practices</a></li>
 
<li><a href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Practices">Human Practices</a></li>
Line 803: Line 861:
 
<ul class="main-Content">
 
<ul class="main-Content">
 
<li>
 
<li>
−
<span class="title">Protocols</span>
+
<span class="title">Collaborations</span>
 
<ul class="sub-Content">
 
<ul class="sub-Content">
−
<li><a href="#First1">Preparation of Competent Cells (<i>E.coli</i>)</a></li>
+
<li><a href="#First1">NCTU iGEM Conference</a></li>
−
<li><a href="#First2">DNA Dissolution</a></li>
+
<li><a href="#First2">Team HSNU-TAIPEI</a></li>
−
<li><a href="#First3">Agarose Gel Electrophoresis</a></li>
+
<li><a href="#First3">Mingdao</a></li>
−
<li><a href="#First4">Gel Extraction</a></li>
+
−
<li><a href="#First5">DNA Ligation</a></li>
+
−
<li><a href="#First6">Plasmid DNA Extraction Using Alkaline Lysis Method (<i>E.coli</i>)</a></li>
+
−
<li><a href="#First7">Transformation (<i>E.coli</i>)</a></li>
+
−
<li><a href="#First8">Protein Extraction</a></li>
+
−
<li><a href="#First9">SDS-PAGE</a></li>
+
−
<li><a href="#First10">Western Blot</a></li>
+
−
<li><a href="#First11">Immunostaining</a></li>
+
 
</ul>
 
</ul>
 
</li>
 
</li>
Line 851: Line 901:
 
<div class="ContentHolder">
 
<div class="ContentHolder">
  
−
<div class="Text1" id="First1"><Red>Preparation of Competent Cells (<i>E.coli</i>)</Red></div>
+
<div class="Text1"><Red>Collaborations</Red></div>
−
<div class="Text2">
+
<div class="Text2" id="First1">
−
<Green>Materials and Reagents :</Green>
+
<Green>NCTU iGEM Conference</Green>
 
</div>
 
</div>
 +
<div class="Text3">
 +
Three of our members joined the International Genetically Engineered Machine Conference at National Chiao Tung University from July 19<sup>th</sup> to 23<sup>rd</sup> 2015. As a simple warm-up for the upcoming world championship in Boston, it was an Asian regional platform for teams from different countries to exchange ideas and explore synthetic biology. And we received questions and precious suggestions from other participants after presentation and poster time, which turned out to better improve our project design :
 +
</div>
 
<div class="Text3">
 
<div class="Text3">
 
<ol class="part2">
 
<ol class="part2">
−
<li><i>Escherichia coli</i> DH5α</li>
+
<li>Will <i>L. casei</i> secret too many CPP-PYY complexes and cause people unwilling to eat for a long term of time, which might cause malnutrition?</li>
−
<li>LB broth</li>
+
<li>Will your product affect the sensitivity of hypothalamus to PYY? And is there a safety maximum concentration of PYY in blood?</li>
−
<li>TB buffer</li>
+
<li>How do you measure the concentration of PYY in blood?</li>
−
<li>DMSO</li>
+
<li>How long will your product stay in human body?</li>
−
<li>Liquid nitrogen</li>
+
<li>When should people take the capsule? Before or after meal? And how many times should people take the capsule a day?</li>
 +
<li>How do you measure the concentration of PYY in blood?</li>
 +
<li>Can gastrointestinal tract digest CPP-PYY complex before it gets through intestinal membrane?</li>
 +
<li>Question from TCU: Why not use a patch instead?</li>
 +
<li>Suggestion from ZJU-China:</li>
 +
<div class="Text3">(1) We suggest you change the suicide mechanism, because there’s only one promoter before the gene circuit of CPP-PYY and CI. This might cause <i>L. casei</i> die before it works.</div>
 +
<div class="Text3">(2) Will holin and endolysin in the suicide mechanism harm other cells? Why not change suicide mechanism into quorum sensing?</div>
 +
<li>What is your product’s positioning? Is it used as food or as medicine?</li>
 +
<li>As we know, <i>L. casei</i> is prokaryote. Can your CPP-PYY complex fold correctly through <i>L. casei</i>?</li>
 +
<li>Will patients be hungrier after they stop taking capsule?</li>
 +
<li>Will immune response arouse by CPP-PYY complex?</li>
 +
<li>Is there any chance that plasmid transfer to other cells and affect the colony in intestine?</li>
 +
<li>Is pLP825 too small for the three parts of genes to fit in?</li>
 +
<li>We know that appetite is controlled by several chemical compounds, such as PYY and leptin. When the concentration of PYY in blood rises, will the concentration of leptin decrease? Will our body naturally balance out the effect from PYY?</li>
 
</ol>
 
</ol>
 
</div>
 
</div>
−
<div class="Text3">
+
<div class="Container_Article_Picture1">
−
 
+
<div class="Article_Picture1">
−
<i>Escherichia coli</i> DH5α
+
<img src="https://static.igem.org/mediawiki/2015/6/61/NTU_Poster_Time.jpg" width="465px"/>
 +
<div class="Article_Spacing"></div>
 +
<div class="Article_PictureText1"><div class="Text_Picture">[Fig.1-1] We introduced our project during poster time</div></div>
 +
</div>
 +
</div>
 +
<div class="Container_Article_Picture2">
 +
<div class="Article_Picture2">
 +
<img src="https://static.igem.org/mediawiki/2015/a/a3/NTU_iGEM_Conference.jpg" width="550px"/>
 +
<div class="Article_Spacing"></div>
 +
<div class="Article_PictureText2"><div class="Text_Picture">[Fig.1-2] All teams in the conference</div></div>
 +
</div>
 
</div>
 
</div>
  
  
  
 +
<div class="Text2" id="First2">
 +
Team HSNU-TAIPEI
 +
</div>
 +
<div class="Text3">
 +
We shared plasmid which we have prepared from Biobrick (BBa_B0015) with team HSNU-TAIPEI, and helped them with the restriction site design in DNA synthesis.
 +
</div>
 +
<div class="Text2" id="First3">
 +
Mingdao
 +
</div>
 +
<div class="Text3">
 +
On 8/27 2015, we had a meeting with team Mingdao in Nation Taiwan University for improving the whole project and sharing the experience with each other.
 +
</div>
 +
<div class="Container_Article_Picture3">
 +
<div class="Article_Picture3">
 +
<img src="https://static.igem.org/mediawiki/2015/b/b1/NTU_Mingdao1.jpg" width="550px"/>
 +
<div class="Article_Spacing"></div>
 +
<div class="Article_PictureText3"><div class="Text_Picture">[Fig.3-1] Mingdao's presentation</div></div>
 +
</div>
 +
</div>
 +
<div class="Container_Article_Picture3">
 +
<div class="Article_Picture3">
 +
<img src="https://static.igem.org/mediawiki/2015/e/e2/NTU_Mingdao2.jpg" width="550px"/>
 +
<div class="Article_Spacing"></div>
 +
<div class="Article_PictureText3"><div class="Text_Picture">[Fig.3-2] NTU-LIHPAO-Taiwan's presentation</div></div>
 +
</div>
 +
</div>
 +
<div class="Container_Article_Picture3">
 +
<div class="Article_Picture3">
 +
<img src="https://static.igem.org/mediawiki/2015/5/59/NTU_Mingdao3.jpg" width="550px"/>
 +
<div class="Article_Spacing"></div>
 +
<div class="Article_PictureText3"><div class="Text_Picture">[Fig.3-3] NTU-LIHPAO-Taiwan and Mingdao</div></div>
 +
</div>
 +
</div>
  
  
Line 898: Line 1,007:
 
if (target.length) {
 
if (target.length) {
 
$('html,body').animate({
 
$('html,body').animate({
−
scrollTop: target.offset().top-15
+
scrollTop: target.offset().top-55
 
}, 700);
 
}, 700);
 
return false;
 
return false;

Latest revision as of 13:24, 18 September 2015

NTU-LIHPAO-Taiwan

Collaborations
NCTU iGEM Conference
Three of our members joined the International Genetically Engineered Machine Conference at National Chiao Tung University from July 19th to 23rd 2015. As a simple warm-up for the upcoming world championship in Boston, it was an Asian regional platform for teams from different countries to exchange ideas and explore synthetic biology. And we received questions and precious suggestions from other participants after presentation and poster time, which turned out to better improve our project design :
  1. Will L. casei secret too many CPP-PYY complexes and cause people unwilling to eat for a long term of time, which might cause malnutrition?
  2. Will your product affect the sensitivity of hypothalamus to PYY? And is there a safety maximum concentration of PYY in blood?
  3. How do you measure the concentration of PYY in blood?
  4. How long will your product stay in human body?
  5. When should people take the capsule? Before or after meal? And how many times should people take the capsule a day?
  6. How do you measure the concentration of PYY in blood?
  7. Can gastrointestinal tract digest CPP-PYY complex before it gets through intestinal membrane?
  8. Question from TCU: Why not use a patch instead?
  9. Suggestion from ZJU-China:
    10. (1) We suggest you change the suicide mechanism, because there’s only one promoter before the gene circuit of CPP-PYY and CI. This might cause L. casei die before it works.
    (2) Will holin and endolysin in the suicide mechanism harm other cells? Why not change suicide mechanism into quorum sensing?
  10. What is your product’s positioning? Is it used as food or as medicine?
  11. As we know, L. casei is prokaryote. Can your CPP-PYY complex fold correctly through L. casei?
  12. Will patients be hungrier after they stop taking capsule?
  13. Will immune response arouse by CPP-PYY complex?
  14. Is there any chance that plasmid transfer to other cells and affect the colony in intestine?
  15. Is pLP825 too small for the three parts of genes to fit in?
  16. We know that appetite is controlled by several chemical compounds, such as PYY and leptin. When the concentration of PYY in blood rises, will the concentration of leptin decrease? Will our body naturally balance out the effect from PYY?
[Fig.1-1] We introduced our project during poster time
[Fig.1-2] All teams in the conference
Team HSNU-TAIPEI
We shared plasmid which we have prepared from Biobrick (BBa_B0015) with team HSNU-TAIPEI, and helped them with the restriction site design in DNA synthesis.
Mingdao
On 8/27 2015, we had a meeting with team Mingdao in Nation Taiwan University for improving the whole project and sharing the experience with each other.
[Fig.3-1] Mingdao's presentation
[Fig.3-2] NTU-LIHPAO-Taiwan's presentation
[Fig.3-3] NTU-LIHPAO-Taiwan and Mingdao
Maintained by the iGEM team NTU-LIHPAO-Taiwan    ©2015 NTU-LIHPAO-Taiwan